Scancell Holdings (SCLP) RNS Announcements

Add to Alert list
Date Time Source Announcement
11 Jul 2017 07:00 AM
RNS
Continued Progress on SCIB1
26 Jun 2017 07:00 AM
RNS
DNA ImmunoBody Patent Granted in Europe
22 May 2017 12:59 PM
RNS
Holding(s) in Company
19 May 2017 02:47 PM
RNS
Holding(s) in Company
19 May 2017 07:00 AM
RNS
Holding(s) in Company
11 May 2017 12:09 PM
RNS
Results of Placing
11 May 2017 07:00 AM
RNS
Proposed Placing to Raise up to £5.0 million
13 Apr 2017 12:39 PM
RNS
Change of Registered Office
20 Mar 2017 07:00 AM
RNS
Immuno-Oncology Summit Europe 2017
13 Mar 2017 07:15 AM
RNS
Hardman Research: SCIB development update
01 Mar 2017 07:00 AM
RNS
Holding(s) in Company
31 Jan 2017 07:00 AM
RNS
Interim Results
30 Jan 2017 07:00 AM
RNS
Partnership to Advance Lung Cancer Clinical Trials
03 Jan 2017 11:33 AM
RNS
Research Update - Amendment
03 Jan 2017 07:00 AM
RNS
Research Update
14 Nov 2016 07:00 AM
RNS
World Immunotherapy Congress and Biotech and Money
18 Oct 2016 05:42 PM
RNS
Results of AGM
10 Oct 2016 07:00 AM
RNS
Preparing SCIB2 for clinical study in lung cancer
26 Sep 2016 07:15 AM
RNS
Hardman Report: New frontiers in T-cell activation
23 Sep 2016 05:24 PM
RNS
Notice of AGM - Amendment
23 Sep 2016 03:28 PM
RNS
Notice of AGM
16 Sep 2016 07:00 AM
RNS
Final Results
07 Sep 2016 07:00 AM
RNS
NewsMakers in the Biotech Industry Conference
22 Aug 2016 07:00 AM
RNS
Appointment of Non-Executive Director
21 Jul 2016 07:00 AM
RNS
Eurogentec manufacturing agreement
20 Jul 2016 07:00 AM
RNS
Extension to Ichor Commercial Option
13 Jul 2016 07:00 AM
RNS
Peer-reviewed publication on Moditope® platform
06 Jul 2016 07:00 AM
RNS
SCIB1 compelling survival data in melanoma
29 Jun 2016 04:40 PM
RNS
Second Price Monitoring Extn
29 Jun 2016 04:35 PM
RNS
Price Monitoring Extension
17 Jun 2016 07:00 AM
RNS
SCIB1 Drug Product Supply
02 Jun 2016 07:00 AM
RNS
Development of ImmunoBody® Vaccine
18 May 2016 07:00 AM
RNS
Opens US Headquarters in San Diego
19 Apr 2016 07:00 AM
RNS
Director/PDMR Shareholding
11 Apr 2016 04:11 PM
RNS
Holding(s) in Company
06 Apr 2016 07:00 AM
RNS
Holding(s) in Company
04 Apr 2016 10:17 AM
RNS
Result of the open offer
01 Apr 2016 07:00 AM
RNS
Result of open offer
23 Mar 2016 07:00 AM
RNS
World Cancer Vaccine Congress
11 Mar 2016 07:00 AM
RNS
Posting of Circular
11 Mar 2016 07:00 AM
RNS
Strategic collaboration with Karolinska Institutet
09 Mar 2016 02:07 PM
RNS
Placing and Open Offer Close
09 Mar 2016 07:00 AM
RNS
Proposed Placing and Open Offer
23 Feb 2016 07:00 AM
RNS
Presenting at the Biotech Capital Conference
27 Jan 2016 09:00 AM
RNS
Amendment to Options
27 Jan 2016 07:00 AM
RNS
Half Yearly Report
11 Jan 2016 07:00 AM
RNS
SCIB1 Early Immune Effect Observed by ImmunTraCkeR
07 Jan 2016 07:00 AM
RNS
Directorate Change
05 Jan 2016 07:00 AM
RNS
Key Moditope paper published in Cancer Research
18 Dec 2015 07:00 AM
RNS
US Phase II combination study with SCIB1

Scancell Holdings PLC is a biopharmaceutical company that develops vaccines and other therapies to treat cancer and infectious diseases. Scancell's research focuses on the human immune system and how to use it to develop new treatments. Scancell uses four technology platforms to develop its products: ImmunoBody, Moditope, GlyMab and AvidiMab.

Scancell was founded in 1997 based on research led by Professor Lindy Durrant at the University of Nottingham.

Scancell Holdings PLC is listed on the London Stock Exchange (LSE) as SCLP.

Scancell share price listed at 8p in 2010.

UK 100

Latest directors dealings